BioCryst Pharmaceuticals, Inc.
(NASDAQ : BCRX)

( )
BCRX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -13.49%265.330.0%$3803.52m
BNTXBioNTech SE -18.67%279.830.0%$1221.54m
NVAXNovavax, Inc. -11.60%141.8678.2%$678.26m
AMGNAmgen, Inc. 3.14%208.791.4%$636.09m
GILDGilead Sciences, Inc. -0.09%69.501.0%$509.20m
LGVNLongeveron Inc. 0.65%20.250.0%$468.87m
VRTXVertex Pharmaceuticals, Inc. 0.61%205.061.9%$451.31m
REGNRegeneron Pharmaceuticals, Inc. -1.60%625.002.7%$399.60m
ILMNIllumina, Inc. 1.26%351.653.3%$324.62m
SNSSSunesis Pharmaceuticals, Inc. 2.68%4.210.7%$294.29m
BIIBBiogen, Inc. 0.09%224.111.8%$281.34m
SGENSeagen Inc. -3.14%146.015.8%$152.04m
INCYIncyte Corp. -1.17%65.012.4%$146.25m
EXASEXACT Sciences Corp. 5.55%80.8418.0%$141.11m
BMRNBioMarin Pharmaceutical, Inc. 1.56%84.244.2%$134.04m

Company Profile

BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever. The company was founded in 1986 and is headquartered in Durham, NC.